Article: article from journal or magazin.
Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma.
Publication types: Journal Article ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
MAGE genes encode tumor-specific shared antigens that are among the most interesting candidates for cancer vaccines. Despite extensive studies, however, CD8+ T-cell responses to MAGE-derived epitopes have been detected only occasionally in cancer patients, even after vaccination. In contrast with these findings, we report here that HLA-A2 melanoma patients respond frequently to the recently identified peptide MAGE-A10(254-262). Indeed, as assessed by staining with fluorescent HLA-A2/peptide MAGE-A10(254-262) tetramers, CD8+ T cells directed against this peptide were readily detectable in a large proportion of HLA-A2+ melanoma patients. These results provide new insight into the immunogenicity of MAGE antigens and underline the potential usefulness of MAGE-A10 peptide-based cancer vaccines.
Animals, Antibodies, Monoclonal, Antigens, Neoplasm, COS Cells, Cytotoxicity, Immunologic, DNA, Recombinant, Dose-Response Relationship, Drug, HLA-A2 Antigen, Humans, Melanoma, Neoplasm Proteins, Oligopeptides, Plasmids, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Tumor Necrosis Factor-alpha
Web of science
Last modification date